JapanAn article reports that the U.S. plan to impose a 100% tariff on generic drug imports could threaten India's pharmaceutical industry's access to its largest market, which accounts for about 37% of its $26 billion in pharma exports. The potential tariff is expected to increase pressure on Indian companies to shift toward producing higher-value medicines. Shares of several drugmakers have declined due to concerns over the difficulty of relocating production to the U.S.
Bias read (Center): The article presents the U.S. tariff policy as a potential threat to India's pharmaceutical industry without overtly endorsing or criticizing either side. It focuses on economic implications and industry responses rather than taking a clear ideological stance. The framing remains balanced by citing
